Together, these studies uncover novel compensatory pathways that may be involved ... Key among these is the activation of signaling by RHO (another member of the RAS superfamily) and the up ...

RTKs can activate Ras, a protein that is tethered to the plasma ... such as the alteration of key proteins and changes in gene transcription. Signal binding to membrane receptor tyrosine kinases ...

About 20% of patients with RASopathies have HCM; RASopathy-associated HCM is often caused by genetic mutations in the RAS/MAPK signaling pathway, which regulates cell growth and development.

Blaustein and colleagues concluded that activation of the PI 3-kinase signaling pathway by Ras(V12-C40) in turn activated AKT kinase, resulting in a change in the fibronectin splicing pattern to ...

Human cell transformation systems revealed that RAL-GEF signaling is particularly required for oncogenic RAS function in human ... Co-opted pathways required by oncogenic KRAS in order to sustain ...

which drives the RAS/MAPK signaling pathway. More information: Keren Cheng et al, Defining the cellular origin of seminoma by transcriptional and epigenetic mapping to the normal human germline ...

Advance Novel, Early-stage Pipeline to Create Multiple Opportunities to Demonstrate Potentially Transformative Outcomes in RAS/MAPK Pathway-driven ... to block MEK signaling without the ...

RAS genes constitute the most regularly mutated oncogene family in cancer. Indeed, RAS genes constituted the most regularly mutated oncogenes in the top three causes of cancer deaths in the US in ...

By the late 1990s, scientists had managed to identify drugs that worked against mutant proteins that function in specific signaling pathways that cancer cells rely on—a step that ushered in a ...

Aberrant activation of the Ras/Raf/MAPK/ERK kinase/extracellular signal-regulated kinase cascade and the VEGF pathway are commonly observed in breast cancer cells leading to malignant cell ...

Inhibition of PI3K signaling in tumors has metabolic ... The combination of Hsp90 inhibitors with RAF or MEK inhibitors may achieve a better pathway inhibition in RAS and/or BRAF mutant tumors. This ...

"With the addition of VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, we are well-positioned to further establish our leadership in targeting RAS/MAPK pathway-driven cancers ...